

**Notice regarding Differences in the Non-consolidated Financial Results  
between the Fiscal Year Ended March 31, 2024 and the Previous Fiscal Year**

Osaka, Japan, May 9, 2024 - Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Toichi Takino; “the Company”) today announced that there were differences in the non-consolidated financial results (Japanese standard) between the fiscal year ended March 2024 (April 1, 2023 to March 31, 2024) and the previous fiscal year.

**1. Differences in the full-year non-consolidated financial results between the fiscal year ended March 2024 and the previous fiscal year**

(Unit: Millions of yen, except basic earnings per share)

	Revenues	Operating Profit	Ordinary Profit	Net Profit for the year	Basic earnings per share (yen)
Previous Results (A) (FY ended March 2023)	441,242	152,004	150,755	117,190	239.96
Actual Results (B) (FY ended March 2024)	498,777	187,916	188,036	152,909	318.51
Change (B–A)	57,535	35,912	37,280	35,719	—
Change (%)	13.0	23.6	24.7	30.5	—

**2. Reasons for the differences**

In addition to the increased sales of major new products such as Forxiga Tablets for the treatment of diabetes, chronic heart failure and chronic kidney disease, etc., and an increase in royalty income, the Company recorded the lump-sum payment of ¥17.0 billion associated with the settlement of the litigation on patents with AstraZeneca UK Limited. Due to these factors, there were differences in the full-year non-consolidated financial results between the fiscal year ended March 31, 2024 and the previous fiscal year.

**Contact:**

Ono Pharmaceutical Co., Ltd.  
Corporate Communications  
[public\\_relations@ono-pharma.com](mailto:public_relations@ono-pharma.com)